The missing comparator: Why MS drug risks are clear, but MS disease risks are not

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1. 1Data-driven risk/benefit estimator for multiple sclerosis therapies2024
2. 2Risks and benefits of multiple sclerosis therapies: need for continual assessment?Risk Assessment · 2011 · 19 citations
3. 3Extrapolating from trials to clinic: a predictive model defining the boundaries of benefit for multiple sclerosis therapies in real-world populations based on systematic reviewmeta-analysis · 2026 · 3 citations
4. 4Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple SclerosisCohort Study · 2022 · 57 citations
5. 5Progressive multiple sclerosis treatment considerations in the UK: Experience from trials and real-world population review · 2024
6. 6EFFICACY AND SAFETY OF HIGH-EFFICACY VERSUS MODERATE-EFFICACY DMTS IN EARLY RELAPSING-REMITTING MS: A NARRATIVE REVIEWSystematic Review · 2026
7. 7The UK patient experience of relapse in Multiple Sclerosis treated with first disease modifying therapiesOriginal Research · 2014 · 30 citations
8. 8Management of Multiple Sclerosis: Incorporating Recent Advances in Pathophysiology and Diagnosis to Guide Treatment StrategiesOriginal Research · 2026
9. 9Catalogue of the Castniidae in the National Museum of Ireland - Natural History, Dublin, with general comments on the history of the collection (Insecta: Lepidoptera)SHILAP Revista de lepidopterología · 2026
10. 10Integrative Taxonomic Characterization and first DNA Barcoding of Chrysozephyrus syla (Kollar, [1844]) and C. birupa (Moore, 1877) for Indian species (Lepidoptera: Lycaenidae)SHILAP Revista de lepidopterología · 2026